{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:01:52Z","timestamp":1792677712147,"version":"4.5.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The present study investigated the survival benefit of non\u2013anthracycline (ANT)-based vs ANT-based regimens in a large-scale, real-world cohort of patients with extranodal natural killer (NK)\/T-cell lymphoma, nasal type (ENKTCL). Within the China Lymphoma Collaborative Group (CLCG) database (2000-2015), we identified 2560 newly diagnosed patients who received chemotherapy with or without radiotherapy. Propensity score matching (PSM) and multivariable analyses were used to compare overall survival (OS) and progression-free survival (PFS) between the 2 chemotherapy regimens. We explored the survival benefit of non\u2013ANT-based regimens in patients with different treatments in early-stage disease and in risk-stratified subgroups. Non\u2013ANT-based regimens significantly improved survivals compared with ANT-based regimens. The 5-year OS and PFS were 68.9% and 59.5% for non\u2013ANT-based regimens compared with 57.5% and 44.5% for ANT-based regimens in the entire cohort. The clinical advantage of non\u2013ANT-based regimens was substantial across the subgroups examined, regardless of stage and risk-stratified subgroup, and remained significant in early-stage patients who received radiotherapy. The survival benefits of non\u2013ANT-based regimens were consistent after adjustment using multivariable and PSM analyses. These findings provide additional evidence supporting non\u2013ANT-based regimens as a first-line treatment of patients with ENKTCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001852","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T22:36:43Z","timestamp":1594939003000},"page":"3141-3153","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["First-line non\u2013anthracycline-based chemotherapy for extranodal nasal-type NK\/T-cell lymphoma: a retrospective analysis from the CLCG"],"prefix":"10.1182","volume":"4","author":[{"given":"Shu-Nan","family":"Qi","sequence":"first","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4241-9972","authenticated-orcid":false,"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qin","family":"Song","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital\u2013Chongqing Cancer Hospital, Chongqing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[{"name":"Jiangsu Cancer Hospital\u2013Jiangsu Institute of Cancer Research, Nanjing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4672-1981","authenticated-orcid":false,"given":"Chen","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Lin","family":"Qu","sequence":"additional","affiliation":[{"name":"The General Hospital of Chinese People\u2019s Liberation Army, Beijing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Qian","sequence":"additional","affiliation":[{"name":"The Affiliated Provincial Hospital of Anhui Medical University, Hefei, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Rong","family":"Hou","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences\u2013Peking Union Medical College, Beijing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Quan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences\u2013Peking Union Medical College, Beijing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ying","family":"Qiao","sequence":"additional","affiliation":[{"name":"The Fourth Hospital of Hebei Medical University, Shijiazhuang, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Second Affiliated Hospital of Nanchang University, Nanchang, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Hospital, National Geriatric Medical Center, Beijing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Qiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2659-6354","authenticated-orcid":false,"given":"Yu-Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Zhong","family":"Cao","sequence":"additional","affiliation":[{"name":"Shanxi Cancer Hospital and the Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Xin","family":"Wu","sequence":"additional","affiliation":[{"name":"Fujian Provincial Cancer Hospital, Fuzhou, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Yu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital\u2013Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Shi","sequence":"additional","affiliation":[{"name":"Xijing Hospital of Fourth Military Medical University, Xi\u2019an, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ming","family":"Xu","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention\u2013Therapy, National Clinical Research Center for Cancer, Tianjin, People\u2019s Republic of China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention\u2013Therapy, National Clinical Research Center for Cancer, Tianjin, People\u2019s Republic of China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[{"name":"The Fifth Medical Center of PLA General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0985-235X","authenticated-orcid":false,"given":"Ye-Xiong","family":"Li","sequence":"additional","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People\u2019s Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"issue":"25","key":"2021060816012133800_B1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"16","key":"2021060816012133800_B2","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/cncr.30697","article-title":"The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States","volume":"123","author":"Vargo","year":"2017","journal-title":"Cancer"},{"issue":"7","key":"2021060816012133800_B3","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/leu.2015.44","article-title":"Prognostic nomogram for overall survival in previously untreated patients with extranodal NK\/T-cell lymphoma, nasal-type: a multicenter study","volume":"29","author":"Yang","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2021060816012133800_B4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","article-title":"Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma","volume":"24","author":"Li","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021060816012133800_B5","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2021060816012133800_B6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamaoncol.2016.5094","article-title":"Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer\/T-cell lymphoma","volume":"3","author":"Yang","year":"2017","journal-title":"JAMA Oncol"},{"issue":"33","key":"2021060816012133800_B7","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"32","key":"2021060816012133800_B8","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/JCO.2012.45.6541","article-title":"Concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211","volume":"30","author":"Yamaguchi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"35","key":"2021060816012133800_B9","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021060816012133800_B10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ejh.12405","article-title":"Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer\/T-cell lymphoma","volume":"94","author":"Tsai","year":"2015","journal-title":"Eur J Haematol"},{"issue":"2","key":"2021060816012133800_B11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cncr.27752","article-title":"First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE\/IIE extranodal natural killer\/T-cell lymphoma","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"2021060816012133800_B12","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00277-014-2137-6","article-title":"Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK\/T cell lymphoma: CISL08-01 phase II study","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol"},{"issue":"11","key":"2021060816012133800_B13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1634\/theoncologist.2014-0305","article-title":"A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I\/II extranodal natural killer\/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group","volume":"19","author":"Kim","year":"2014","journal-title":"Oncologist"},{"issue":"1","key":"2021060816012133800_B14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijrobp.2018.05.046","article-title":"Phase 2 study of first-line intensity modulated radiation therapy followed by gemcitabine, dexamethasone, and cisplatin for high-risk, early stage extranodal nasal-type NK\/T-cell lymphoma: the GREEN study","volume":"102","author":"Qi","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2021060816012133800_B15","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2021060816012133800_B16","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2021060816012133800_B17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12032-014-0860-4","article-title":"Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE\/IIE extranodal natural killer\/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up","volume":"31","author":"Wang","year":"2014","journal-title":"Med Oncol"},{"issue":"11","key":"2021060816012133800_B18","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1080\/10428194.2019.1602265","article-title":"Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG)","volume":"60","author":"Qi","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2021060816012133800_B19","article-title":"Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making","author":"Chen","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2021060816012133800_B20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021060816012133800_B21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"2021060816012133800_B22","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/14737140.2017.1344100","article-title":"L-Asparaginase for newly diagnosed extra-nodal NK\/T-cell lymphoma: systematic review and meta-analysis","volume":"17","author":"Pokrovsky","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2021060816012133800_B23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14737140.2019.1549992","article-title":"Defining the toxicity of current regimens for extranodal NK\/T cell lymphoma: a systematic review and metaproportion","volume":"19","author":"Pokrovsky","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"2021060816012133800_B24","doi-asserted-by":"crossref","first-page":"e190194","DOI":"10.1001\/jamanetworkopen.2019.0194","article-title":"Risk-dependent conditional survival and failure hazard after radiotherapy for early-stage extranodal natural killer\/T-cell lymphoma","volume":"2","author":"Liu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"19","key":"2021060816012133800_B25","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.18632\/aging.102331","article-title":"Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK\/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG)","volume":"11","author":"Liu","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"11","key":"2021060816012133800_B26","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1080\/10428194.2019.1599111","article-title":"Upfront radiation is essential for high-risk early-stage extranodal NK\/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era","volume":"60","author":"Qi","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2021060816012133800_B27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2018.04.026","article-title":"Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK\/T-cell lymphoma: a multicenter study from the China Lymphoma Collaborative Group (CLCG)","volume":"129","author":"Deng","year":"2018","journal-title":"Radiother Oncol"},{"issue":"18","key":"2021060816012133800_B28","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/bloodadvances.2018021311","article-title":"Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2021060816012133800_B29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan","volume":"35","author":"Yamaguchi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021060816012133800_B30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/annonc\/mdx684","article-title":"Sequential chemotherapy\/radiotherapy was comparable with concurrent chemoradiotherapy for stage I\/II NK\/T-cell lymphoma","volume":"29","author":"Kwong","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"2021060816012133800_B31","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3026(19)30283-2","article-title":"Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell project","volume":"7","author":"Fox","year":"2020","journal-title":"Lancet Haematol"},{"issue":"12","key":"2021060816012133800_B32","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1038\/bcj.2014.88","article-title":"Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell lymphoma","volume":"4","author":"Ke","year":"2014","journal-title":"Blood Cancer J"},{"key":"2021060816012133800_B33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.10.011","article-title":"A phase II study of methotrexate, etoposide, dexamethasone and pegaspargase sandwiched with radiotherapy in the treatment of newly diagnosed, stage IE to IIE extranodal natural-killer\/T-cell lymphoma, nasal-type","volume":"25","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"3","key":"2021060816012133800_B34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2015.07.2267","article-title":"Concurrent chemoradiation therapy followed by consolidation chemotherapy for localized extranodal natural killer\/T-cell lymphoma, nasal type","volume":"93","author":"Oh","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2021060816012133800_B35","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3109\/10428194.2014.939964","article-title":"Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer\/T-cell lymphoma: a multicenter retrospective study","volume":"56","author":"Wang","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2021060816012133800_B36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00277-014-2244-4","article-title":"Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK\/T cell lymphoma treated with L-asparaginase-containing chemotherapy\u2013a single institution experience","volume":"94","author":"Zang","year":"2015","journal-title":"Ann Hematol"},{"issue":"7","key":"2021060816012133800_B37","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1002\/cam4.2214","article-title":"Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE\/IIE extranodal natural killer\/T-cell lymphoma, nasal type","volume":"8","author":"Tian","year":"2019","journal-title":"Cancer Med"},{"issue":"4","key":"2021060816012133800_B38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/COC.0000000000000647","article-title":"Study of L-asparaginase, vincristine, and dexamethasone combined with intensity-modulated radiation therapy in early-stage nasal NK\/T-cell Lymphoma","volume":"43","author":"Hu","year":"2020","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"2021060816012133800_B39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428194.2019.1663421","article-title":"Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer\/T-cell lymphoma: a retrospective single-center study","volume":"61","author":"Wei","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2021060816012133800_B40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/ejh.13004","article-title":"Efficacy and tolerance of GELOXD\/P-GEMOXD in newly diagnosed nasal-type extranodal NK\/T-cell lymphoma: a multicenter retrospective study","volume":"100","author":"Li","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"2021060816012133800_B41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-014-2171-4","article-title":"Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer\/T-cell lymphoma patients","volume":"94","author":"Kim","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"2021060816012133800_B42","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12032-014-0435-4","article-title":"Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III\/IV extranodal natural killer\/T cell lymphoma","volume":"32","author":"Wang","year":"2015","journal-title":"Med Oncol"},{"issue":"12","key":"2021060816012133800_B43","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.3109\/10428194.2014.907894","article-title":"A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer\/T-cell lymphoma, nasal type","volume":"55","author":"Ji","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2021060816012133800_B44","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00277-015-2336-9","article-title":"Treatment outcome of patients with advanced stage natural killer\/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy","volume":"94","author":"Bi","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"2021060816012133800_B45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12185-015-1809-x","article-title":"High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed\/refractory extranodal natural killer\/T cell lymphoma: a retrospective study","volume":"102","author":"Ding","year":"2015","journal-title":"Int J Hematol"},{"issue":"3","key":"2021060816012133800_B46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-014-2228-4","article-title":"Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III\/IV NK\/T cell-lymphoma, nasal type (NTCL)","volume":"94","author":"Kim","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"2021060816012133800_B47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02983387","article-title":"L-asparaginase-based regimen in the treatment of refractory midline nasal\/nasal-type T\/NK-cell lymphoma","volume":"78","author":"Yong","year":"2003","journal-title":"Int J Hematol"},{"issue":"7","key":"2021060816012133800_B48","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00277-008-0669-3","article-title":"L-asparaginase in the treatment of refractory and relapsed extranodal NK\/T-cell lymphoma, nasal type","volume":"88","author":"Yong","year":"2009","journal-title":"Ann Hematol"},{"issue":"11","key":"2021060816012133800_B49","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-014-2136-7","article-title":"Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed\/refractory extranodal NK\/T cell lymphoma: a retrospective study of 17 patients","volume":"93","author":"Zhou","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"2021060816012133800_B50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-6-44","article-title":"A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK\/T-cell lymphoma, nasal type","volume":"6","author":"Lin","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2021060816012133800_B51","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3892\/mco.2014.368","article-title":"Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK\/T-cell lymphoma","volume":"2","author":"Guo","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"2021060816012133800_B52","first-page":"2589","article-title":"Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer\/T-cell lymphoma patients receiving asparaginase-based chemotherapy","volume":"8","author":"Wang","year":"2015","journal-title":"OncoTargets Ther"},{"issue":"5","key":"2021060816012133800_B53","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2559.2004.01867.x","article-title":"NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status","volume":"44","author":"Ko","year":"2004","journal-title":"Histopathology"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2021005072","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3141\/1808986\/advancesadv2020001852.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3141\/1808986\/advancesadv2020001852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T17:03:37Z","timestamp":1623171817000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/13\/3141\/461313\/First-line-non-anthracycline-based-chemotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":53,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001852","relation":{"correction":[{"id-type":"doi","id":"10.1182\/bloodadvances.2021005072","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]}}}